These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 32891427)

  • 1. Re: Primary Chemoablation of Low-grade Upper Tract Urothelial Carcinoma Using UGN-101, a Mitomycin-containing Reverse Thermal Gel (OLYMPUS): An Open-label, Single-arm, Phase 3 Trial.
    Ourfali S; Colombel M
    Eur Urol; 2021 Jan; 79(1):162. PubMed ID: 32891427
    [No Abstract]   [Full Text] [Related]  

  • 2. Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial.
    Kleinmann N; Matin SF; Pierorazio PM; Gore JL; Shabsigh A; Hu B; Chamie K; Godoy G; Hubosky S; Rivera M; O'Donnell M; Quek M; Raman JD; Knoedler JJ; Scherr D; Stern J; Weight C; Weizer A; Woods M; Kaimakliotis H; Smith AB; Linehan J; Coleman J; Humphreys MR; Pak R; Lifshitz D; Verni M; Adibi M; Amin MB; Seltzer E; Klein I; Konorty M; Strauss-Ayali D; Hakim G; Schoenberg M; Lerner SP
    Lancet Oncol; 2020 Jun; 21(6):776-785. PubMed ID: 32631491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comment on "Durability of response to primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel: OLYMPUS trial final report".
    Song Y; Du Y; Qin C; Xu T
    World J Urol; 2022 May; 40(5):1251-1252. PubMed ID: 35191990
    [No Abstract]   [Full Text] [Related]  

  • 4. Durability of Response to Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma Using UGN-101, a Mitomycin-Containing Reverse Thermal Gel: OLYMPUS Trial Final Report.
    Matin SF; Pierorazio PM; Kleinmann N; Gore JL; Shabsigh A; Hu B; Chamie K; Godoy G; Hubosky SG; Rivera M; O'Donnell M; Quek M; Raman JD; Knoedler JJ; Scherr D; Weight C; Weizer A; Woods M; Kaimakliotis H; Smith AB; Linehan J; Coleman J; Humphreys MR; Pak R; Lifshitz D; Verni M; Klein I; Konorty M; Strauss-Ayali D; Hakim G; Seltzer E; Schoenberg M; Lerner SP
    J Urol; 2022 Apr; 207(4):779-788. PubMed ID: 34915741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The ablative effect of mitomycin reverse thermal gel: Expanding the role for nephron preservation therapy in low grade upper tract urothelial carcinoma.
    Kaimakliotis HZ; Tachibana I; Woldu S; Labbate C; Jacob J; Murray K; Rose K; Sexton W; Dickstein R; Linehan J; Nieder A; Bjurlin M; Humphreys M; Ghodoussipour S; Quek M; O'Donnell M; Eisner BH; Matin SF; Lotan Y; Feldman AS
    Urol Oncol; 2023 Sep; 41(9):387.e1-387.e7. PubMed ID: 37246135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Mitomycin Gel (UGN-101) as an Adjuvant Therapy After Complete Endoscopic Management of Upper Tract Urothelial Carcinoma.
    Labbate C; Woldu S; Murray K; Rose K; Sexton W; Tachibana I; Kaimakliotis H; Jacob J; Dickstein R; Linehan J; Nieder A; Bjurlin M; Humphreys M; Ghodoussipour S; Quek M; O'Donnell M; Eisner B; Feldman A; Lotan Y; Matin SF
    J Urol; 2023 May; 209(5):872-881. PubMed ID: 36657029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An evaluation of UGN-101, a sustained-release hydrogel polymer-based formulation containing mitomycin-C, for the treatment of upper urothelial carcinomas.
    Porta C; Giannatempo P; Rizzo M; Lucarelli G; Ditonno P; Battaglia M
    Expert Opin Pharmacother; 2020 Dec; 21(18):2199-2204. PubMed ID: 32870051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary Chemoablation of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer Using UGN-102, a Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2b, Open-Label, Single-Arm Trial.
    Chevli KK; Shore ND; Trainer A; Smith AB; Saltzstein D; Ehrlich Y; Raman JD; Friedman B; D'Anna R; Morris D; Hu B; Tyson M; Sankin A; Kates M; Linehan J; Scherr D; Kester S; Verni M; Chamie K; Karsh L; Cinman A; Meads A; Lahiri S; Malinowski M; Gabai N; Raju S; Schoenberg M; Seltzer E; Huang WC
    J Urol; 2022 Jan; 207(1):61-69. PubMed ID: 34433303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of UGN-101, a mitomycin-containing reverse thermal gel instilled via retrograde catheter for the treatment of low-grade upper tract urothelial carcinoma.
    Shabsigh A; Kleinmann N; Smith AB; Scherr D; Seltzer E; Schoenberg M; Lerner SP
    Cancer Chemother Pharmacol; 2021 Jun; 87(6):799-805. PubMed ID: 33677615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An evaluation of mitomycin-containing reverse thermal gel for the treatment of low-grade upper tract urothelial carcinoma.
    Head DJ; Raman JD
    Expert Rev Anticancer Ther; 2024 Oct; 24(10):943-948. PubMed ID: 39129535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. UGN-101 (mitomycin gel): a novel treatment for low-grade upper tract urothelial carcinoma.
    Kokorovic A; Matin SF
    Ther Adv Med Oncol; 2020; 12():1758835920937950. PubMed ID: 32670424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Editorial Comment: Adjuvant Single-Dose Upper Urinary Tract Instillation of Mitomycin C After Therapeutic Ureteroscopy for Upper Tract Urothelial Carcinoma: A Single-Centre Prospective Non-Randomized Trial.
    de Carvalho JPM
    Int Braz J Urol; 2021; 47(1):193-195. PubMed ID: 33047926
    [No Abstract]   [Full Text] [Related]  

  • 13. Response to Okeke and Rai:"Adjuvant Single-Dose Upper Urinary Tract Instillation of Mitomycin C After Therapeutic Ureteroscopy for Upper Tract Urothelial Carcinoma: A Single-Center Prospective Nonrandomized Trial" by Gallioli et al.
    Territo A; Gallioli A; Breda A
    J Endourol; 2020 Jul; 34(7):793-794. PubMed ID: 32640847
    [No Abstract]   [Full Text] [Related]  

  • 14. Technique of mitomycin C instillation in the treatment of upper urinary tract urothelial tumors.
    Eastham JA; Huffman JL
    J Urol; 1993 Aug; 150(2 Pt 1):324-5. PubMed ID: 8326553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of urothelial carcinoma of the upper urinary tract following prostatocystectomy with mitomycin C instillation in the ileal loop.
    van Helsdingen PJ; Rikken CH
    J Urol; 1986 Aug; 136(2):461-3. PubMed ID: 3090277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ureteroscopic and percutaneous management of upper tract urothelial carcinoma (UTUC): systematic review.
    Cutress ML; Stewart GD; Zakikhani P; Phipps S; Thomas BG; Tolley DA
    BJU Int; 2012 Sep; 110(5):614-28. PubMed ID: 22471401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Percutaneous management of upper tract transitional cell carcinoma.
    Streem SB; Pontes EJ
    J Urol; 1986 Apr; 135(4):773-5. PubMed ID: 3083119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re: Alison Birtle, Mark Johnson, John Chester, et al. Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma (the POUT Trial): A Phase 3, Open-label, Randomised Controlled Trial. Lancet 2020;395:1268-77: A New Standard for a Rare Disease? Optimizing the Timing of Chemotherapy for Upper Tract Urothelial Carcinoma.
    Singla N; Margulis V;
    Eur Urol; 2021 Jan; 79(1):e28. PubMed ID: 33008662
    [No Abstract]   [Full Text] [Related]  

  • 19. Re: Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma (the POUT Trial): A Phase 3, Open-label, Randomised Controlled Trial.
    D'Andrea D; Pradere B; Shariat SF
    Eur Urol; 2021 Jan; 79(1):163-164. PubMed ID: 32981804
    [No Abstract]   [Full Text] [Related]  

  • 20. Re: Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma (the POUT Trial): A Phase 3, Open-label, Randomised Controlled Trial.
    Kuusk T; Bex A
    Eur Urol; 2020 Oct; 78(4):630-631. PubMed ID: 32451179
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.